NCCN Oncology Research Program (ORP)
NCCN ORP Mission Statement
The NCCN ORP fosters innovation and knowledge discovery that improve the lives of patients with cancer.
Guiding Principles:
- Study both FDA-approved and investigational agents/devices, to seek novel enhanced, effective, and efficient cancer therapy.
- Develop new insights into cancer care delivery outcomes and quality, as well as identify solutions to barriers affecting optimal cancer management.
- Increase opportunities for NCCN Member Institution faculty to participate in oncologic investigation and support those who are, or will become, leaders in cancer research.
- Demonstrate that constructive, appropriate, and transparent collaboration between academia and industry results in valuable knowledge and improved cancer management.
- Ensure the dissemination of knowledge gained through the program to the medical community at large through presentations at meetings and/or publication in peer-reviewed journals.
Current Opportunities
NCCN and Taiho Request for Proposals (RFP) Grant Opportunity: Phase I/II Clinical Trials of Zipalertinib (CLN 081/TAS 6417) for Non-Small Cell Lung Cancers with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Uncommon/Compound Mutations – Submit Proposals by Monday, January 6, 2025. Open to NCCN Member Institutions only.
View the NCCN ORP Press Releases
View the NCCN ORP Scientific Publications
View the NCCN ORP Disclosure Policy